SCHEMBL4430871

SCHEMBL4430871

O=C(O)c1cccn(C(c2ccc(F)cc2)c2ccc(F)cc2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
METTL3 Q86U44 1/20 0.40
METTL14 Q9HCE5 1/20 0.40
CYP1A2 P05177 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
ALOX12 P18054 1/20 0.38
CACNA2D1 P54289 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNB1 Q02641 1/20 0.37
CACNA1C Q13936 1/20 0.37
CYP19A1 P11511 1/20 0.37
PTGS2 P35354 2/20 0.37
KMT2A Q03164 3/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4427312 0.87 ALDH1A1 (0.43) KDM4ELMNAMETTL3METTL14ALDH1A1
SCHEMBL4994701 0.84 KDM4E (0.43) KDM4EALDH1A1HPGDCACNA2D1CACNA1B
SCHEMBL4991196 0.84 HDAC4 (0.40) METTL3METTL14KMT2ACNR2OPRK1
SCHEMBL4429636 0.83 SLC6A4 (0.47) KDM4ELMNACYP1A2ALDH1A1GAA
SCHEMBL4989816 0.78 TTR (0.39) KDM4ELMNAALDH1A1GAAMAPT
SCHEMBL4987904 0.78 CES2 (0.43) KDM4EALDH1A1GAAMAPTPTGS2
SCHEMBL1944076 0.77 PTGS2 (0.58) KDM4ELMNAALDH1A1MAPTHPGD
SCHEMBL4991582 0.75 POLB (0.42) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL1243603 0.75 KCNA5 (0.46) CYP3A4CYP2C9CYP19A1CYP2C19DHODH
SCHEMBL4430634 0.75 CACNA2D1 (0.44) KDM4ELMNACYP1A2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 KDM4E 2635/4885LMNA 809/4885METTL3 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.